Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Advances deployment of mRNA technology across vaccines and therapeutics development
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Innovative solutions and a deep understanding of the market makes this a unique combination
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
Subscribe To Our Newsletter & Stay Updated
